4/17
04:05 pm
tovx
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
High
Report
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
3/23
08:00 am
tovx
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
High
Report
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
3/12
08:38 am
tovx
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results [Yahoo! Finance]
Low
Report
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results [Yahoo! Finance]
3/12
08:00 am
tovx
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Low
Report
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
2/18
08:00 am
tovx
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Medium
Report
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
2/3
08:00 am
tovx
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Medium
Report
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026